Biocartis Group NV (FRA:8XB) EBIT: €-51.94 Mil (TTM As of Jun. 2023)


FRA:8XB Biocartis Group NV FRA:8XB
14 GF Score
Price €0.26
View Full Analysis

What is Biocartis Group NV EBIT?

Biocartis Group NV FRA:8XB 14 EBIT is €-51.94 Mil as of Jun. 2023. GuruFocus rates FRA:8XB with a GF Score™ of 14/100.

Biocartis Group NV's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2023 was €-21.64 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was €-51.94 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biocartis Group NV's annualized ROC % for the quarter that ended in Jun. 2023 was -51.54%. Biocartis Group NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -76.29%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Biocartis Group NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -34.30%.


Biocartis Group NV  (FRA:8XB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biocartis Group NV's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

ROC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-40.83 * ( 1 - 0.07% )/( (77.414 + 80.901)/ 2 )
=-40.801419/79.1575
=-51.54 %

where

Note: The Operating Income data used here is two times the semi-annual (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Biocartis Group NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Jun. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-43.282/( ( (31.527 + max(21.942, 0)) + (30.004 + max(29.991, 0)) )/ 2 )
=-43.282/( ( 53.469 + 59.995 )/ 2 )
=-43.282/56.732
=-76.29 %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(16.697 + 18.905 + 8.192) - (11.938 + 0 + 9.914)
=21.942

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(21.313 + 17.884 + 5.221) - (6.902 + 0 + 7.525)
=29.991

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biocartis Group NV's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2023 )
=-51.944/151.440
=-34.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocartis Group NV EBIT Related Terms


Biocartis Group NV EBIT Historical Data

* Premium members only.

The historical data trend for Biocartis Group NV's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocartis Group NV EBIT Chart

Biocartis Group NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -46.90 -57.07 -52.98 -62.40 -54.43

Biocartis Group NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.78 -29.61 -24.13 -30.30 -21.64

FRA:8XB vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, Biocartis Group NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocartis Group NV EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocartis Group NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biocartis Group NV's EV-to-EBIT falls into.


FRA:8XB
14GF Score
Biocartis Group NV FRA:8XB
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocartis Group NV EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-51.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-51.94 Mil mean?
Biocartis Group NV (FRA:8XB) has a EBIT of €-51.94 Mil as of Jun. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Biocartis Group NV.
Is Biocartis Group NV's EBIT too high?
Biocartis Group NV's current EBIT is €-51.94 Mil. Overall, Biocartis Group NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Biocartis Group NV's EBIT compare to TMO and DHR?
Biocartis Group NV's EBIT of €-51.94 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Biocartis Group NV. Biocartis Group NV's current EBIT is €-51.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocartis Group NV stock overvalued right now?
Biocartis Group NV (FRA:8XB) has a current EBIT of €-51.94 Mil. The current EBIT is €-51.94 Mil. Biocartis Group NV's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Biocartis Group NV (FRA:8XB), the current EBIT is €-51.94 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biocartis Group NV Business Description

Address Generaal de Wittelaan 11 B, Mechelen, BEL, 2800
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an Meet Idylla molecular diagnostic system for oncology and infectious disease segments.
14GF Score

Get the complete analysis for FRA:8XB

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.26
Price